Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Unutilized manufacturing capacity & CMO wind-down by Year
Unutilized manufacturing capacity & CMO wind-down charges ($M) ($M)
Moderna Unutilized manufacturing capacity & CMO wind-down: $263M in FY2024, down 73.2% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“Cost of sales for the full year 2024 was $1.5 billion, or 47% of net product sales, inclusive of third-party royalties of $155 million, inventory write-downs of $495 million, wind-down costs of $263 million, and unutilized manufacturing capacity of $105 million.”
Source: Q4 2024 Earnings Release (8-K) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unutilized manufacturing capacity & CMO wind-down charges ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 263 | -73.2% | Q4 2024 Earnings Release (8-K) ↗ |
| FY2023 | Dec 31, 2023 | 981 | +26.4% | Q4 2023 Earnings Release (8-K) ↗ |
| FY2022 | Dec 31, 2022 | 776 | – | Q4 2022 Earnings Release (8-K) ↗ |
Cite this data
StockData. (2026). Moderna Unutilized manufacturing capacity & CMO wind-down ($M), annual FY2022–FY2024 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-unutilized-winddown
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.